Oseltamivir (Tamiflu) is considered safe during pregnancy and is the preferred antiviral for treating influenza in pregnant women at any trimester. The CDC, the American College of Obstetrics and Gynecology, and the Infectious Diseases Society of America all recommend prompt treatment with oseltamivir when a pregnant person has suspected or confirmed flu.
What the Safety Evidence Shows
Oseltamivir carries an FDA “Pregnancy Category C” label, which means no controlled clinical trials have been done in pregnant women. That label sounds cautious, but the FDA itself clarifies that Category C does not mean the drug can’t or shouldn’t be used during pregnancy. It means that observational data, rather than randomized trials, form the evidence base.
And there’s a substantial amount of observational data. Multiple large studies have tracked outcomes in pregnant women who took oseltamivir, and they consistently show no increased risk of adverse pregnancy or fetal outcomes. A post-marketing safety review covering 2,926 maternal exposures found rates of spontaneous miscarriage (2.9%), therapeutic abortion (1.8%), and preterm delivery (4.2%) that were all lower than background rates in the general population. A review of 81 reported birth defect cases found no pattern suggesting oseltamivir was the cause.
Risk of Birth Defects
The most detailed look at congenital malformations comes from a Danish population study that compared 406 first-trimester exposures against more than 670,000 unexposed pregnancies. After adjusting for confounding factors, the odds ratio for any major congenital malformation was 0.94, meaning exposed pregnancies had essentially the same rate of birth defects as unexposed ones. The crude numbers initially suggested a possible link to congenital heart defects, but once researchers accounted for differences between the groups using propensity-score matching, the association dropped to a statistically nonsignificant odds ratio of 1.75, with wide confidence intervals that crossed 1.0.
A separate U.S. study found that 6.7% of first-trimester-exposed pregnancies involved a major birth defect, compared to 7.9% in unexposed pregnancies. That relative risk of 0.84 reinforces the conclusion: oseltamivir does not appear to raise the risk of birth defects.
Why Treatment Matters More Than the Risk
Influenza itself poses real dangers during pregnancy. Pregnant women are at higher risk of severe flu illness, and a CDC study published in The Lancet Infectious Diseases found that flu during pregnancy is associated with reduced birthweight in full-term newborns and an increased risk of pregnancy loss after 13 weeks. Pregnant women with respiratory symptoms and fever also face higher rates of preterm birth. These are the risks you’re weighing against the theoretical concerns of a Category C medication.
Starting oseltamivir early makes a significant difference. Treatment begun within two days of symptom onset reduced the risk of death by roughly 73% compared to later treatment, and by 84% compared to no treatment at all, in a pooled analysis of studies on pregnant and postpartum women. Early treatment also shortened hospital stays and lowered the chance of ICU admission and mechanical ventilation. Japan, where 92% of pregnant women with pandemic flu received antivirals within 48 hours, saw notably fewer severe outcomes than other countries during the 2009 H1N1 pandemic.
Dosing During Pregnancy
The standard treatment dose is 75 mg twice daily for five days. However, pregnancy changes how the body processes this drug. The kidneys filter blood more rapidly during pregnancy, which clears the active form of oseltamivir from the bloodstream faster than in non-pregnant adults. A pharmacokinetic study found significantly lower blood levels of the drug’s active metabolite in pregnant women compared to non-pregnant women taking the same dose.
Some researchers have suggested increasing the dose to 75 mg three times daily during pregnancy to compensate. The CDC notes that higher dosing may be considered in specific situations, though safety data on increased doses in pregnancy are limited. Your prescriber will make this call based on the severity of your illness and how far along you are.
Safety While Breastfeeding
Oseltamivir passes into breast milk in very small amounts. At the standard dose, a breastfed infant would receive roughly 0.5% of the mother’s weight-adjusted dose. To put that in perspective, infants older than two weeks of age can be prescribed oseltamivir directly at doses hundreds of times higher than what they’d get through breast milk. The amounts in milk are not expected to cause any adverse effects in a nursing infant, and there is no recommendation to stop breastfeeding while taking oseltamivir.
What This Means in Practice
If you’re pregnant and develop flu symptoms, the evidence strongly favors treatment over waiting. Oseltamivir is the first-choice antiviral because it has the most safety data behind it, and every major medical organization in the U.S. endorses its use during all three trimesters and the first two weeks postpartum (including after pregnancy loss). The drug is also recommended for prevention if you’ve been closely exposed to someone with confirmed flu.
The key factor that improves outcomes is speed. Starting treatment within 48 hours of your first symptoms provides the greatest benefit in reducing complications, hospital time, and mortality risk. Waiting for a positive test result before beginning treatment is not recommended if flu is clinically suspected.